Mckesson Corp (MCK) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$899.56

Open

$895.57

Day range

$887.29 – $896.98

Volume

784K

About Mckesson Corp

Latest MCK news

• Walmart heirs Olivia and Tom Walton are committing $100 million to America’s maternal death crisis—and betting states and donors will pour in more
  Fortune · Sep 15, 2026

  Philanthropists Olivia and Tom Walton have announced a significant $100 million commitment to combat the maternal mortality crisis in the United States. This five-year investment is part of their initiative, Healthy Moms, Healthy Babies America (HMHBA), which aims to reduce maternal deaths by 50%. The Waltons are positioning this funding as seed money, with the expectation that states and other donors will contribute additional resources to amplify the impact of their efforts. The maternal mortality rate in the U.S. has been a growing concern, with recent data indicating that it is among the highest in developed nations. The Waltons' investment is not only a philanthropic endeavor but also a strategic bet on the potential for public-private partnerships to address this urgent health issue. By galvanizing state and donor support, the initiative could lead to a more coordinated approach to maternal health, potentially influencing healthcare policies and funding allocations at both state and federal levels. Market implications of this initiative could be significant, particularly for healthcare providers and organizations focused on maternal and child health. Companies involved in healthcare technology, maternal health services, and community health initiatives may see increased interest and investment as stakeholders respond to the Waltons' call for action. Additionally, this commitment could spur further philanthropic investment in the sector, as other wealthy individuals and organizations may seek to align with the Waltons' vision and contribute to improving maternal health outcomes across the country.

• McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
  Yahoo Finance · Sep 6, 2026

  McKesson Corporation has announced its intention to acquire Precision Medicine Group for approximately $2.25 billion, marking a significant move in its strategy to enhance its oncology services. This acquisition, which is expected to be finalized in the coming months, will integrate Precision Medicine's clinical research and biopharma commercialization capabilities into McKesson’s oncology unit, further solidifying its position in the oncology market. The deal underscores McKesson's commitment to expanding its footprint in precision medicine, an area poised for growth as personalized therapies become increasingly vital in cancer treatment. By incorporating Precision Medicine's expertise, McKesson aims to improve patient outcomes and streamline the development and distribution of oncology therapies. Market analysts suggest that this acquisition could enhance McKesson's competitive edge against other major players in the healthcare sector, particularly as the demand for innovative cancer treatments continues to rise. Investors may view this acquisition positively, as it aligns with broader trends in the pharmaceutical industry focusing on personalized medicine. However, the financial implications of the deal will depend on how effectively McKesson can integrate Precision Medicine's operations and realize synergies. As the healthcare landscape evolves, McKesson's strategic investments in oncology could position the company favorably for future growth amidst increasing competition and regulatory challenges.

• McKesson strikes $2.25 billion Precision Medicine deal in clinical research bets
  Forex News · Aug 25, 2026

  McKesson Corporation has announced its acquisition of Precision Medicine Group for approximately $2.25 billion, marking a significant move in the healthcare sector aimed at enhancing its clinical research capabilities. This acquisition is part of McKesson's broader strategy to expand its offerings in precision medicine, which tailors treatments to individual patient profiles, thereby improving outcomes and efficiency in drug development. The deal underscores a growing trend in the pharmaceutical industry where companies are increasingly investing in personalized medicine to stay competitive. By integrating Precision Medicine Group's expertise in biopharma commercialization and clinical research services, McKesson aims to bolster its position in the rapidly evolving healthcare landscape. Market analysts suggest that this acquisition could lead to increased revenue streams for McKesson, as it aligns with the industry's shift towards more targeted therapies and personalized healthcare solutions. Investors may view this acquisition positively, as it reflects McKesson's commitment to innovation and growth in a sector that is becoming increasingly lucrative. However, the financial implications will depend on the successful integration of Precision Medicine Group's operations and the realization of projected synergies. As the healthcare market continues to evolve, McKesson's strategic investments in precision medicine could play a pivotal role in shaping its future performance.

• M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
  IPO & M&A · Aug 25, 2026

  McKesson Corporation has announced its intention to acquire Precision Medicine Group, a strategic move aimed at enhancing its capabilities in oncology and multispecialty services. This acquisition is expected to bolster McKesson's trial execution and expand its end-to-end offerings, which include drug development and market access solutions. The deal underscores McKesson's commitment to integrating advanced precision medicine into its service portfolio, potentially positioning the company as a leader in the rapidly evolving oncology market. In a separate development, Lundbeck has partnered with Eversana to leverage artificial intelligence in its operations. This collaboration aims to enhance Lundbeck's drug development processes and improve patient engagement through AI-driven insights. The partnership reflects a growing trend in the pharmaceutical industry, where companies are increasingly turning to technology to streamline operations and enhance patient outcomes. Both developments indicate a broader shift towards innovation in healthcare, with significant implications for market dynamics as companies seek to differentiate themselves in a competitive landscape.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen